Administration other than IV or IM. Increased risk of CV & thrombotic adverse events associated w/ COX-2 inhibitors when taken long term appears to be similar in those w/ or w/o known CV disease or CV risk factors. Most at risk of developing GI complications w/ NSAIDS are the elderly, patients w/ CV disease, concomitant use w/ aspirin, corticosteroids, SSRIs or other NSAIDs, or alcohol intake or w/ history or active GI disease eg, ulceration, bleeding or inflammatory conditions. W/ or w/o history of sulfonamide allergy. Discontinue use at the 1st appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. Severe hypotension may occur. Concomitant use w/ anticoagulants. Can lead to the onset of new HTN or worsening of preexisting HTN. Monitor BP closely during initiation of & throughout the course of therapy. Compromised cardiac function, preexisting edema, or other conditions predisposing to, or worsened by, fluid retention including those on diuretic therapy or at risk of hypovolemia. Monitor renal function closely in patients w/ advanced renal disease. Rehydrate patients prior to & at initiation of therapy. Moderate hepatic impairment (Child-Pugh Class B). May diminish the utility of diagnostic signs eg, fever in detecting infections; avoid concomitant use w/ other non-specific NSAIDs. Consider withdrawal in women who have difficulties conceiving or who are undergoing infertility investigation. Pregnant women on parecoxib should be closely monitored for amniotic fluid vol. Lactation. Childn <18 yr.